{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:09:45Z","timestamp":1781680185161,"version":"3.54.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["BIOT"],"published-print":{"date-parts":[[2019,8,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Protein misfolding is a critical factor in the progression of a large number\nof neurodegenerative diseases. The incorrectly folded protein is prone to aggregation, leading to\naberrant interaction with other cellular proteins, elevated oxidative stress, impaired cellular machinery,\nfinally resulting in cell death. Due to its monogenic origin, Huntington\u2019s disease (HD) is\na poster child of protein misfolding neurodegenerative disorders. The presence of neuronal inclusions\nof mutant huntingtin N-terminal fragments, mainly in the cortex and striatum, is a neuropathological\nhallmark of HD. Inhibition of protein misfolding and aggregation has been attempted\nusing a variety of conventional protein stabilizers.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This review describes how, in recent times, nucleic acid therapeutics has emerged as a\nselective tool to downregulate the aberrant transcript and reduce expression of mutant huntingtin,\nthereby alleviating protein aggregation. Different strategies of use of nucleic acids, including antisense\noligonucleotides, short inhibitory RNA sequences and aptamers have been discussed. The\nfollowing patent databases were consulted: European Patent Office (EPO), the United States Patent\nand Trademark Office (USPTO), Patent scope Search International and National Patent Collections\n(WIPO) and Google Patents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Tools such as RNA interference (RNAi) and antisense oligonucleotides (ASOs) are potential\ntherapeutic agents which target the post-transcriptional step, accelerating mRNA degradation\nand inhibiting the production of the mutant protein. These nucleic acid sequences not only\ntarget the elongated CAG triplet repeat translating to an expanded polyglutamine tract in the mutant\nprotein, but have also been used to target single nucleotide polymorphisms associated with the\nmutant allele. The therapeutic sequences have been investigated in a number of cells and animal\nmodels of HD. One antisense sequence, with desirable safety properties, has recently shown\ndownregulation of huntingtin protein in a limited clinical trial. RNA aptamers have also shown\npromising results in inhibiting protein aggregation in a yeast model of HD. Novel drug delivery\ntechniques have been employed to overcome the blood brain barrier for the use of these therapeutic\nsequences.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The selectivity and specificity imparted by nucleic acids, along with novel delivery\ntechniques, make them hopeful candidates for the development of a curative strategy for HD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872208313666190208163714","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T10:45:51Z","timestamp":1549968351000},"page":"187-206","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nucleic Acid Therapeutics in Huntington\u2019s Disease"],"prefix":"10.2174","volume":"13","author":[{"given":"Kuljit","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab 160062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab 160062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Recent Patents on Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T07:06:06Z","timestamp":1573715166000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169844\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872208313666190208163714","relation":{},"ISSN":["1872-2083"],"issn-type":[{"value":"1872-2083","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}